RxDoctor Payments Data

Elyse Mills

Family · Ruston, LANPI 1417505413

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 405 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,490 and has fallen 97.2% since, to $70 in 2025. Among family clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,852in general payments, 2019–2025

Across 405 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Acadia Pharmaceuticals Inc$603
  • Neurocrine Biosciences, Inc.$556
  • SK Life Science, Inc.$457
  • Biogen$427
  • Teva Pharmaceuticals USA, Inc.$357
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,840100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,852 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Medicare billing

Part B allowed, 2024
$13,745
Medicare patients
59
Services billed
1,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ajovy SyringeFremanezumab-Vfrm11$8,289
Levetiracetam11$157

Paid to pharmacies, not to this prescriber.

Other family in Ruston

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →